NTG Clarity Networks Inc provides digital transformation solutions software development outsourcing and software products. The group provides engineering, Information Technology, networking services, and developing niche software products for telecommunications and utilities. It also expanded into the financial and government sectors, providing technical resources and products to assist customers with projects that include digital transformation.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
100.0%
暂无批准数据
- The AACR strongly opposes an OMB proposed rule that would subject federal research funding decisions to political review, undermining the scientific peer review process. - The proposal could allow politically appointed officials to terminate active multi-year grants and clinical trials based on shifting political priorities rather than scientific merit. - New restrictions on international collaborations, conference attendance, and publication costs would slow the dissemination of discoveries and impede global cancer research partnerships. - The U.S. cancer death rate has fallen 35% since 1991 under the current merit-based system, saving over 4.8 million lives, progress the AACR warns is now at risk.
- A phase II clinical trial demonstrated that patients with alveolar soft part sarcoma can safely receive atezolizumab immunotherapy beyond the standard two-year treatment period without increased toxicity. - Among 17 patients treated for more than two years, only three experienced moderate-to-severe treatment-related adverse events, all of which were manageable and resolved with dose adjustments or additional medications. - The findings are particularly significant for adolescents and young adults with this ultra-rare cancer, who may require extended treatment periods and could live for many years with metastatic disease. - No patients discontinued treatment due to adverse events, and researchers observed no late toxicities typically associated with long-term immunotherapy use in other cancer types.
- FYR Bio and NuvOx Therapeutics received a two-year $1,976,897 Direct-to-Phase II SBIR award from the National Cancer Institute to integrate liquid biopsy technology into glioblastoma treatment. - The collaboration will apply FYR's EV-Omics platform to NuvOx's Phase IIb RESTORE trial testing NanO₂, a radiosensitizer designed to reverse tumor hypoxia in glioblastoma patients. - The partnership aims to develop extracellular vesicle biomarkers that can help clinicians differentiate pseudoprogression from true tumor progression, addressing a persistent challenge in glioblastoma management. - NanO₂ has demonstrated positive results in two completed Phase Ib/II studies and was identified as the most promising oxygen therapeutic among 74 clinical-stage compounds in a literature review.
- PDS Biotech's PDS01ADC met RECIST v1.1 criteria for expansion to Stage 2 of a Phase 2 trial in metastatic colorectal cancer, achieving at least 6 objective responses in 9 patients. - The novel antibody-drug conjugate combines IL-12 with NHS76 antibody to target tumor necrosis regions while minimizing systemic IL-12 exposure and associated toxicities. - The NCI-led study will expand enrollment to 22 patients total, with completion of recruitment anticipated by Q4 2025 for this deadly cancer affecting over 150,000 Americans annually.
- NIH researchers report that a new form of tumor infiltrating lymphocyte (TIL) therapy combined with pembrolizumab achieved 23.5% objective response rate in patients with metastatic gastrointestinal cancers, compared to 7.7% with selected TILs alone. - The clinical trial included 91 heavily pretreated patients with various gastrointestinal cancers, demonstrating efficacy across multiple tumor types including colon, rectal, pancreatic, and bile duct cancers. - Response durations ranged from 4 months to 3.5 years in the combination therapy group, offering new hope for extending cell-based immunotherapies to common solid tumors that have historically been resistant to such approaches.
• Dr. Joseph Sparano was recognized as a 2024 Giant of Cancer Care for his work in breast cancer and HIV-associated cancer, focusing on underserved communities. • Sparano led pivotal trials like TAILORx, which refined treatment for ER-positive, HER2-negative breast cancer by using genomic testing to avoid unnecessary chemotherapy. • His research addresses racial disparities in breast cancer outcomes, including the EAZ171 trial for Black women, and has improved treatments for HIV-associated lymphomas. • Sparano's work extends to mentorship and compassionate care, shaping future oncologists and improving outcomes for diverse patient populations.
- Huntsman Cancer Institute joins myeloMATCH, an NCI-sponsored program, to match AML and MDS patients with tailored clinical trials based on their genetic profiles. - The myeloMATCH program utilizes advanced technology to detect measurable residual disease (MRD), guiding treatment assignments for improved patient outcomes. - This initiative expands treatment options, especially for older or frail patients unsuitable for aggressive chemotherapy or bone marrow transplants. - The program integrates resources from multiple clinical trial networks, aiming to accelerate the development of personalized therapies for blood cancers.
• Researchers have developed TRACeR, a platform enabling the design of proteins that bind to peptide-MHC-I complexes, offering a new approach to target tumor-associated antigens. • TRACeR proteins can be engineered to recognize specific peptide-MHC-I complexes, demonstrating high affinity and specificity for target antigens presented on cancer cells. • The platform's versatility is showcased through the creation of bispecific T-cell engagers (BiTEs) and CAR-T cells, effectively redirecting T cells to kill tumor cells expressing the targeted antigen. • In vivo studies demonstrate that TRACeR-based therapeutics are well-tolerated and elicit potent anti-tumor responses, suggesting potential clinical applications in cancer immunotherapy.
- The myeloMATCH program, a collaboration of leading cancer research organizations, has begun enrolling patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for precision medicine trials. - The program offers advanced biomarker testing to identify genomic and molecular features, matching patients with targeted treatments in a series of Phase 2 studies. - myeloMATCH is structured into four tiers, each providing trial options at different stages of cancer treatment, from initial therapy to managing minimal residual disease. - Researchers aim to enroll 5,000 or more patients, tracking their progress and biomarkers to evaluate clonal evolution and develop more effective therapies.
- The National Institutes of Health (NIH) has initiated the myeloMATCH clinical trial to evaluate precision medicine approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). - The trial will use rapid genetic testing to match patients with AML or MDS to targeted treatments based on the molecular characteristics of their tumors. - myeloMATCH aims to enroll thousands of participants and will analyze blood and bone marrow samples to refine assays and understand treatment resistance mechanisms. - This trial is part of the NCI's precision medicine initiatives, building on the NCI-MATCH trial to improve cancer treatment strategies.
